# GeneDx Holdings Corp. (WGS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Technology / Software. Price $85.99, market value $2.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). GeneDx Holdings Corp. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 1.18**. A PEG of 1.18 is in the range usually read as fairly priced for its growth.
- **Price / sales: 5.6×**. Each dollar of revenue is priced at 5.6×.
- **Price / book: 10.5×**. The shares trade at 10.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -3.0%** (5-yr avg -137.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 69.4%**. GeneDx Holdings Corp. keeps 69.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -20.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -4.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -6.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -28.5%**. Return on all capital, debt included, is -28.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -20.3%**. Each dollar of assets produces -20.3% of profit.

## Growth
- **Revenue growth (1 yr): 40.0%** (3-yr 22.1%/yr, 5-yr 19.0%/yr). Revenue grew 40.0% over the last year, against 19.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 62.4%**. Earnings per share rose 62.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.17**. Debt is 0.17 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.6×**. It would take 0.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 8.70**. A Z-score of 8.70 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. GeneDx Holdings Corp. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -34.0%** (YTD -33.9%, 3-mo 64.7%). The shares are down 34.0% over twelve months including dividends.
- **From 52-week high: -49.7%** (167.0% above the low). Trading 50% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 1.50** (volatility 83%). Beta of 1.50 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=WGS · Page: https://foliofundamentals.com/stocks/wgs

Not investment advice.